AbCellera Biologics (NASDAQ:ABCL – Get Rating) and Affimed (NASDAQ:AFMD – Get Rating) are both medical companies, but which is the better stock? We’ll compare the two companies based on the strength of their profitability, risk, valuation, earnings, institutional ownership, analyst recommendations and dividends.
Risk and Volatility
AbCellera Biologics has a beta of -0.28, which means its stock price is 128% less volatile than the S&P 500. In comparison, Affimed has a beta of 2.51, which means its stock price is 151% more volatile than the S&P 500.
Institutional and Insider Ownership
39.6% of AbCellera Biologics shares are held by institutional investors. Comparatively, 63.5% of Affimed shares are held by institutional investors. 45.8% of the shares of AbCellera Biologics are held by insiders of the company. Strong institutional ownership indicates that hedge funds, endowments, and large fund managers believe a stock will outperform the market over the long term.
This table compares the net margins, return on equity and return on assets of AbCellera Biologics and Affimed.
|Net margins||Return on equity||return on assets|
|AbCellera Organic Products||41.87%||19.72%||15.65%|
This is a breakdown of recent valuations and price targets for AbCellera Biologics and Affimed, as provided by MarketBeat.com.
|Sales Ratings||Hold odds||Buy reviews||Strong buy odds||Rating|
|AbCellera Organic Products||0||0||seven||0||3.00|
AbCellera Biologics currently has a consensus price target of $29.60, indicating a potential upside of 292.57%. Affimed has a consensus price target of $10.60, indicating an upside potential of 241.94%. Given AbCellera Biologics’ possible higher upside, analysts clearly believe that AbCellera Biologics is more favorable than Affimed.
Valuation and benefits
This table compares the revenue, earnings per share (EPS) and valuation of AbCellera Biologics and Affimed.
|Gross revenue||Price/sales ratio||Net revenue||Earnings per share||Price/earnings ratio|
|AbCellera Organic Products||$375.20 million||5.72||$153.46 million||$0.64||11.78|
|asserted||$47.76 million||8.01||-$68.06 million||($0.74)||-4.19|
AbCellera Biologics has higher revenues and profits than Affimed. Affimed trades at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.
AbCellera Biologics beats Affimed on 9 of the 12 factors compared between the two stocks.
About AbCellera Biologics (Get a rating)
AbCellera Biologics Inc. is developing an antibody discovery platform. Its comprehensive artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs completed, in progress or under contract with 36 partners. AbCellera Biologics Inc. has entered into a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
About Affirmed (Get a rating)
Affimed NV, a clinical-stage biopharmaceutical company, is focused on the discovery and development of cancer immunotherapies in the United States, Germany and the rest of Europe. Its lead product candidate is AFM13, which has completed the Phase II clinical study for peripheral T-cell lymphoma; in a Phase IIa clinical trial for CD30 positive lymphoma; and in a phase I clinical trial for Hodgkin’s lymphoma. The Company is also developing AFM24, a tetravalent bispecific epidermal growth factor receptor and CD16A-binding innate cell engager, which is in Phase IIa clinical trials for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate in preclinical development for the treatment of solid tumors. Affimed NV has collaborative agreements with the University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as a research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics BV and changed its name to Affimed NV in October 2014. Affimed NV was founded in 2000 and is headquartered in Heidelberg, Germany.
Get news and reviews for AbCellera Biologics Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for AbCellera Biologics and related companies with MarketBeat.com’s FREE daily newsletter.